Volume 13 Supplement 2

Meeting abstracts from the Annual Conference on Hereditary Cancers 2014

Open Access

Microelements as diagnostic markers of pancreatic cancer

  • Marcin Lener1Email author,
  • Anna Wiechowska-Kozłowska2,
  • Magdalena Muszyńska3,
  • Katarzyna Jaworska-Bieniek1,
  • Grzegorz Sukiennicki1,
  • Katarzyna Kaczmarek1,
  • Tomasz Gromowski1,
  • Wojciech Marciniak3,
  • Anna Jakubowska1 and
  • Jan Lubiński1, 3
Hereditary Cancer in Clinical Practice201513(Suppl 2):A2

https://doi.org/10.1186/1897-4287-13-S2-A2

Published: 26 November 2015

Introduction

Pancreatic cancer is the eighth most commonly diagnosed cancer in the developed world and has one of the worst prognoses of any malignancy with 98% succumbing to their disease within 5 years. Little is known about the etiology of the disease despite significant new insights into the mutation signatures common this disease. Changes in microelements serum levels are reported in pancreatic cancer. In the current study we have examined the levels of Se, Cu, Fe, Zn and Mg in a moderately sized pancreatic cancer population and compared it to a healthy age-matched population.

Material and methods

A total of 84 pancreatic cancer patients and 84 aged-matched healthy controls were enrolled in the study after providing informed consent. The patients with pancreatic cancer were enrolled to the study from the Hospital of the Ministry of Internal Affairs and Administration in Szczecin, Poland. For each pancreatic cancer patient included in this study an unaffected individual registered in International Hereditary Cancer Center, Pomeranian Medical University of Szczecin, was used as a control.

Each person enrolled in the study donated ~10 ml EDTA blood for sufficient serum to be isolated and examined for the elements Se, Cu, Fe, Zn and Mg. The level of Se, Cu, Fe, Zn and Mg, in the serum was determined by mass spectrometry Inductively Coupled Plasma Mass Spectrometry (Elan DRC-e, PerkinElmer).

Results

Table 1

The correlation between serum Se level and the occurrence of pancreatic cancer.

Cancer site

Quartile

Se level (µg/l)

No. of cancer / controls

OR

p- value

Pancreas

I

29.87-55.40

37/5

1

-

 

II

55.90-67.97

31/11

2.62

0.1635

 

III

68.06-79.20

9/33

27.13

<0.0001

 

IV

79.36-137.47

7/35

37

<0.0001

Table 2

The correlation between serum Cu level and the occurrence of pancreatic cancer.

Cancer site

Quartile

Cu level (µg/l)

No. of cancer / controls

OR

p- value

Pancreas

I

695.06-1023.95

9/32

1

-

 

II

1025.88-1175.73

14/27

1.84

0.3256

 

III

1179.38-1421.96

22/19

4.11

0.0058

 

IV

1448.68-2901.35

37/4

32.8

<0.0001

Table 3

The correlation between serum Fe level and the occurrence of pancreatic cancer.

Cancer site

Quartile

Fe level (µg/l)

No. of cancer / controls

OR

p- value

Pancreas

I

138.88-668.75

29/12

1

-

 

II

672.81-921.18

19/22

2.79

0.0429

 

III

931.41-1245.91

13/29

5.39

0.0004

 

IV

1247.89-1631.56

22/20

2.19

0.1151

Table 4

The correlation between serum Zn level and the occurrence of pancreatic cancer.

Cancer site

Quartile

Zn level (µg/l)

No. of cancer / controls

OR

p- value

Pancreas

I

306.12-760.79

23/18

1

-

 

II

765.29-863.96

14/27

2.46

0.0752

 

III

864.59-995.08

21/21

1.27

0.6620

 

IV

995.84-1890.96

25/17

0.86

0.8257

Table 5

The correlation between serum Mg level and the occurrence of pancreatic cancer.

Cancer site

Quartile

Mg level (µg/l)

No. of cancer / controls

OR

p- value

Pancreas

I

11964.63-18616.02

25/16

1

-

 

II

18673.87-20144.41

18/23

1.99

0.1843

 

III

20274.88-21673.70

17/24

2.20

0.1215

 

IV

21775.80-30676.08

22/19

1.34

0.6555

Conclusions

  1. 1.

    There is a very strong correlation between the level of selenium, copper in serum and the occurrence of pancreatic cancers in the Polish population.

     
  2. 2.

    The Se, Cu level in serum may be a useful diagnostic tool of pancreatic cancer.

     
  3. 3.
    Further investigations are needed to determine if Se, Cu levels can be used in:
    1. a.

      differential diagnosis between pancreatic cancer (PC) and non-malignant pancreatic lesions

       
    2. b.

      monitoring of systemic treatment efficiency in PC

       
    3. c.

      identification of prognostic factors of pancreatic tumors

       
    4. d.

      identification of factor of PC causative

       
     

Authors’ Affiliations

(1)
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University
(2)
Division of Health Care Ministry of Internal Affairs and Administration in Szczecin
(3)
Read - Gene, S.A.

Copyright

© Lener et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement